Authors Keywords: vulvar lesions, DNA methylation, human papillomavirus, human immunodeficiency virus Abstract

Vulvar cancer accounts for about 5% of all gynaecological malignancies. Previously, it was regarded as a disease of the elderly because it occurred in women over 60 years old. Its incidence is rising due to the coinfection of human papillomavirus (HPV) and human immunodeficiency virus (HIV). High-risk HPV (HR-HPV) predominantly drives both the premalignant and invasive diseases of the vulva in the young population. Women living with HIV have compromised immunity, and the synergism of HPV and HIV might be responsible for their higher predisposition to anogenital neoplasia. They are at a higher risk of infection with multiple HPV genotypes, multifocal disease, persistent infection, and reactivation of latent infections. Genomic alteration through deoxyribonucleic acid (DNA) methylation by persistent HPV infection is implicated in carcinogenesis through the E6/E7 oncogenic pathway. These epigenetic alterations progressively accumulate in HPV-infected cells and induce cancers over time. Premalignant lesions that display abnormal methylation patterns similar to those in cancerous lesions are likely to progress to malignancy within a short period. Such methylation biomarkers can be used to triage premalignant lesions to treatment or monitoring. This review describes the distribution of HPV genotypes and host cell DNA methylation patterns across vulvar premalignant and invasive lesions.

Author Biographies

AE Sajo, University of Pretoria

Department of Obstetrics and Gynaecology, University of Pretoria, South Africa

MC van Aardt, University of Pretoria

Department of Obstetrics and Gynaecology, University of Pretoria and Department of Obstetrics and Gynaecology, Steve Biko Academic Hospital, South Africa

G Dreyer, University of Pretoria

Department of Obstetrics and Gynaecology, University of Pretoria and Department of Obstetrics and Gynaecology, Steve Biko Academic Hospital, South Africa

Issue Section

Review Articles

License By submitting manuscripts to SAJGO, authors of original articles are assigning copyright to the South African Society of Gynaecologic Oncology (SASGO). Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAJGO for educational and research purposes without obtaining permission.